Welcome To CreATe

Our Mission

The Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium will enroll patients with sporadic and familial forms of amyotrophic lateral sclerosis, frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The goals of the CReATe consortium are to advance therapeutic development for this group of neurodegenerative disorders through study of the relationship between clinical phenotype and underlying genotype, and also through the discovery and development of biomarkers.

CReATe Biomarker Pilot Project Request for Applications 2021

The CReATe Consortium in partnership with the ALS Association, is pleased to announce this request for applications (RFA) to support the discovery and/or validation of biomarkers for ALS or a related disorder (including PLS, HSP, PMA, MSP, and FTD).

Deadline to submit the Letter of Intent is May 7, 2021.

For further details click here.


CReATe Podcasts

The CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.

Listen to "CReATe Podcast" on Spreaker.

All podcasts


CReATe Twitter

CReATe Biorepository

Given the increasing recognition that the development and validation of biomarkers will require collaboration, the CReATe Consortium has established a repository of biological samples collected from patients.

Learn more